Adenoviral PSA vaccine ETBX-071
A cancer vaccine composed of a genetically engineered, replication-deficient adenovirus carrying the gene encoding human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral-PSA vaccine ETBX-071, the adenovirus infects cells and expresses PSA. In turn, PSA activates the immune system and induces a cytotoxic T-lymphocyte (CTL) response against PSA-expressing tumor cells. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer.